Demographic characteristics of study participants. by Lijuan Liu (136685)

Subjects:

Results of Analysis of Co-variance (ANCOVA) for change in parameter predicted by treatment group with pre-treatment value as a covariate. * p < 0.05; ** p < 0.01. by Lijuan Liu (136685)

Subjects:

Comparison of treatment effects between premolar extraction and mandibular third molar extraction groups. * p < 0.05; ** p < 0.01. by Lijuan Liu (136685)

Subjects:

Intraoperative facial and intraoral photographs of the case with mandibular third molar extraction. by Lijuan Liu (136685)

Subjects:

Pretreatment facial, intraoral photographs, and radiographs of the case with premolar tooth extraction. by Lijuan Liu (136685)

Subjects:

Pretreatment facial, intraoral photographs, and radiographs of the case with mandibular third molar extraction. by Lijuan Liu (136685)

Subjects:

The results of KEGG enrichment analysis (Annotation: Circles represent each pathway, and the redder the color, the larger the circle, and the more important it is). by Lin Zhou (141050)

The results of linear mixed model. by Soheila Qanbari (20455173)

Subjects:

The flow of the participants from enrollment to analysis. by Soheila Qanbari (20455173)

Subjects:

Correlation between treatment-induced changes in lumbar motor control and N150 amplitude. by Soheila Qanbari (20455173)

Subjects:

The mean and standard deviation of outcome measures. by Soheila Qanbari (20455173)

Subjects:

Linear relationships (Spearman’s r (p-value)) the treatment-induced changes in clinical and neurophysiological data. by Soheila Qanbari (20455173)

Subjects:

The demographical and clinical characteristics of subjects at baseline. by Soheila Qanbari (20455173)

Subjects:

Electrode montage and electric field distribution simulated with SimNIBS software. by Soheila Qanbari (20455173)

Subjects:

Traits at cellular, leaf, and whole-plant scales which were significantly different [increased (↑) or decreased (↓)] or non-significant between tolerant and sensitive cultivars in... by Ranjeeta Adhikari (9905958)

CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

Subjects:

S4 Fig - by R. J. S. D. Heine (17889199)

Subjects:

S1 Fig - by R. J. S. D. Heine (17889199)

Subjects:

S5 Fig - by R. J. S. D. Heine (17889199)

Subjects:

Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

Subjects: